Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A manufacturing process includes spinning at least one continuous poly(glycerol sebacate) (PGS)/alginate fiber from a polymeric solution comprising PGS and alginate in water, drafting the at least one continuous PGS/alginate fiber in at least one coagulation bath, and drawing the at least one continuous PGS/alginate fiber from the at least one coagulation bath. A yarn includes at least one continuous PGS fiber. A continuous poly(glycerol sebacate) (PGS)/alginate fiber forming system includes a feeding tank holding a polymeric solution of alginate and PGS, a pump, a spinneret, a first coagulation bath, a first winder, a second coagulation bath, a second winder, and a bobbin winder, the system forming at least one continuous PGS/alginate fiber from the polymeric solution of alginate and PGS.

Abstract: A fuel cell membrane electrode assembly includes a substrate and a porous polymer membrane. The substrate includes a woven layer including a yarn of polyvinylidene fluoride (PVDF) fiber. The yarn is 7 to 25 denier. The substrate also includes a nanofiber layer including PVDF nanofibers deposited on the woven layer. The nanofiber layer is 1 to 10 micrometers (?m) thick. The substrate exhibits a porosity of at least 70 percent and is less than 30 ?m thick. The porous polymer membrane is deposited on the nanofiber layer. The substrate is a porous support for a fuel cell membrane. A method of forming a fuel cell membrane electrode assembly includes weaving a woven layer of a yarn including fiber of PVDF. The method also includes depositing a nanofiber layer on the woven layer to form a substrate. The method further includes depositing a porous polymer membrane on the nanofiber layer.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A manufacturing process includes combining a liquid resin with a liquid reactive cross-linking composition to form a reactive core composition. The manufacturing also includes contacting the reactive core composition with a sheath composition including a carrier polymer in a solvent. The manufacturing process further includes wet spinning the reactive core composition with the sheath composition to form a sheath-core fiber including a core including at least one continuous fiber of a reaction product of the liquid resin and liquid cross-linking composition and a sheath surrounding the core. The cross-linking composition reacts with the resin during the wet spinning. The sheath includes the carrier polymer. A continuous poly(glycerol sebacate) urethane (PGSU) fiber comprising PGSU and a continuous PGSU fiber forming system are also disclosed.

Abstract: A manufacturing process includes spinning at least one continuous poly(glycerol sebacate) (PGS)/alginate fiber from a polymeric solution comprising PGS and alginate in water, drafting the at least one continuous PGS/alginate fiber in at least one coagulation bath, and drawing the at least one continuous PGS/alginate fiber from the at least one coagulation bath. A yarn includes at least one continuous PGS fiber. A continuous poly(glycerol sebacate) (PGS)/alginate fiber forming system includes a feeding tank holding a polymeric solution of alginate and PGS, a pump, a spinneret, a first coagulation bath, a first winder, a second coagulation bath, a second winder, and a bobbin winder, the system forming at least one continuous PGS/alginate fiber from the polymeric solution of alginate and PGS.

Abstract: A manufacturing process includes spinning at least one continuous poly(glycerol sebacate) (PGS)/alginate fiber from a polymeric solution comprising PGS and alginate in water, drafting the at least one continuous PGS/alginate fiber in at least one coagulation bath, and drawing the at least one continuous PGS/alginate fiber from the at least one coagulation bath. A yarn includes at least one continuous PGS fiber. A continuous poly(glycerol sebacate) (PGS)/alginate fiber forming system includes a feeding tank holding a polymeric solution of alginate and PGS, a pump, a spinneret, a first coagulation bath, a first winder, a second coagulation bath, a second winder, and a bobbin winder, the system forming at least one continuous PGS/alginate fiber from the polymeric solution of alginate and PGS.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: An article includes a fibrous mat of poly(glycerol sebacate) (PGS) resin and a resin of a hydrogel forming polymer, such as a polyvinyl alcohol (PVOH). Methods of making such articles include electrospinning a combination of PGS resin and PVOH resin to form nanofibers and depositing the nanofibers onto a surface to form the fibrous mat. The mat is suitable for a variety of medical uses, including as a barrier that can be deployed in surgical procedures.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A manufacturing process includes spinning at least one continuous poly(glycerol sebacate) (PGS)/alginate fiber from a polymeric solution comprising PGS and alginate in water, drafting the at least one continuous PGS/alginate fiber in at least one coagulation bath, and drawing the at least one continuous PGS/alginate fiber from the at least one coagulation bath. A yarn includes at least one continuous PGS fiber. A continuous poly(glycerol sebacate) (PGS)/alginate fiber forming system includes a feeding tank holding a polymeric solution of alginate and PGS, a pump, a spinneret, a first coagulation bath, a first winder, a second coagulation bath, a second winder, and a bobbin winder, the system forming at least one continuous PGS/alginate fiber from the polymeric solution of alginate and PGS.